Page 101 - Memoria FEHH - SEHH 2017
P. 101

  PROGRAMA ESPAÑOL DE TRATAMIENTOS EN HEMATOLOGÍA (PETHEMA)
MEMORIA ANUAL 2017
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion- dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017;10(1):131.
• García-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcárcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≤30% blasts. Leukemia. 2017;31(12):2799-806.
• Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chha- bra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2017;23(6):971-9.
• Ivars D, Orero MT, Javier K, Díaz-Vico L, García-Giménez JL, Mena S, Tormos C, Egea M, Pérez PL, Arrizabalaga B, Ruiz MÁ, Yagüe N, Tormo M, Sancho-Tello R, Gomes A, Algueró C, O’Connor JE, Sáez GT, Carbonell F, Collado R. Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: the influence of iron over- load. Clin Biochem. 2017;50(16-17):911-7.
• Nomdedeu M, Pereira A, Calvo X, Colomer J, Solé F, Arias A, Gómez C, Luño E, Cervera J, Arnán M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernández-Rivas JM, Díez-Campelo M, Ortega M, Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leuk Res. 2017;63:85-9.
• Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcárcel D. Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect. Exp Hematol. 2017;48:1-11.
• Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martínez-López J, Tormo M, Esteve J, Pratcorona M, Martínez-Losada C, Solé F, Feliú E, Ribera JM; Spanish PETHEMA Group and the Spanish Society of Hematology. Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mecha- nisms. Genes Chromosomes Cancer. 2017;56(11):810-20.
• Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology. Effi- cacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2018 Jul;59(7):1634-43.
• Ramos F, Pedro C, Tormo M, de Paz R, Font P, Luño E, Caballero M, Solano F, Almagro M, Xicoy B, Jiménez M. Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study. Eur J Cancer Care (Engl). 2017;26(6).
• Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, Hernández-Rivas JM; Span- ish Group for Myelodysplastic Syndromes (GESMD). Multidimensional assessment of patient condition and mu- tational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: a prospective study of the Spanish MDS group. Am J Hematol. 2017;92(9):E534-E541.
101
 



















































































   99   100   101   102   103